Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John de Groot

Showing results (71-80 of 87) with videos related to

Pageof 9
Sort By:
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology Advances|August 2, 2021
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessmentKarine A Al Feghali, James W Randall, Diane D Liu, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
AJNR. American Journal of Neuroradiology|June 26, 2024
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in AdultsBenjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Pageof 9

Showing results (71-80 of 87) with videos related to

Sort By:
Pageof 9
Neuro-Oncology|July 22, 2025
The Use of Minor Response, Volumetric Assessment and Growth Rate Kinetics as Endpoints in Grade 1-3 Glioma Clinical Trials: a RANO perspectiveMartin J van den Bent, Timothy F Cloughesy, Benjamin M Ellingson, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 29, 2023
RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in AdultsPatrick Y Wen, Martin van den Bent, Gilbert Youssef, et al.
Neuro-Oncology Advances|August 2, 2021
Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessmentKarine A Al Feghali, James W Randall, Diane D Liu, et al.
Neuro-Oncology Advances|March 7, 2025
Longitudinal profiling of IDH-mutant astrocytomas reveals acquired RAS-MAPK pathway mutations associated with inferior survivalEduardo Rodriguez Almaraz, Geno A Guerra, Nadeem N Al-Adli, et al.
AJNR. American Journal of Neuroradiology|June 26, 2024
A Neuroradiologist's Guide to Operationalizing the Response Assessment in Neuro-Oncology (RANO) Criteria Version 2.0 for Gliomas in AdultsBenjamin M Ellingson, Francesco Sanvito, Timothy F Cloughesy, et al.
Neuro-Oncology|November 23, 2019
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophagesJohn de Groot, Marta Penas-Prado, Kristin Alfaro-Munoz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Acta Neuropathologica|December 11, 2023
"De novo replication repair deficient glioblastoma, IDH-wildtype" is a distinct glioblastoma subtype in adults that may benefit from immune checkpoint blockadeSara Hadad, Rohit Gupta, Nancy Ann Oberheim Bush, et al.
Neuro-Oncology|April 17, 2018
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastomaBenjamin M Ellingson, Lauren E Abrey, Sarah J Nelson, et al.
Pageof 9